SCHEMBL3266946

SCHEMBL3266946

COCCOc1cccc(CNc2ccc3nc(NCc4ccccc4OC)ccc3c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 0.46
CYP3A4 P08684 7/20 0.46
CYP2D6 P10635 7/20 0.46
CYP2C19 P33261 7/20 0.46
LMNA P02545 6/20 0.46
CLK4 Q9HAZ1 3/20 0.46
ALOX15 P16050 3/20 0.46
MAPK1 P28482 3/20 0.46
USP2 O75604 3/20 0.46
CYP2C9 P11712 2/20 0.46
ALDH1A1 P00352 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
NPC1 O15118 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
NFKB1 P19838 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3267055 0.91 LMNA (0.53) CYP1A2CYP3A4CYP2D6CYP2C19LMNA
SCHEMBL3273137 0.87 LMNA (0.41) CYP1A2CYP3A4CYP2D6CYP2C19LMNA
SCHEMBL3268616 0.85 PDGFRB (0.53) CYP1A2CYP3A4CYP2D6CYP2C19LMNA
SCHEMBL3267065 0.84 MEN1 (0.53) CYP1A2CYP3A4CYP2D6CYP2C19LMNA
SCHEMBL3267038 0.83 LMNA (0.45) CYP1A2CYP3A4CYP2D6CYP2C19LMNA
SCHEMBL3267015 0.80 MEN1 (0.47) CYP1A2CYP3A4CYP2D6CYP2C19LMNA
SCHEMBL3268173 0.80 HIF1A (0.53) CYP1A2CYP3A4CYP2D6CYP2C19LMNA
SCHEMBL3267148 0.80 CYP1A2 (0.54) CYP1A2CYP3A4CYP2D6CYP2C19LMNA
SCHEMBL3268321 0.80 CYP1A2 (0.53) CYP1A2CYP3A4CYP2D6CYP2C19LMNA
SCHEMBL3267059 0.79 HIF1A (0.47) CYP1A2CYP3A4CYP2D6CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399674-B2 Quinolines HOFFMAN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-20120136018-A1 QUINOLINES KOLCZEWSKI SABINE (DE) 2012-05-31 US disclosed
EP-2195296-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-06-16 EP disclosed
US-20090088451-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 US disclosed
WO-2009040290-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088451-A1 QUINOLINES HTR5A, HTR1A, HTR1E CYP1A2 161/4885CYP3A4 329/4885CYP2D6 250/4885
US-20120136018-A1 QUINOLINES HTR5A, HTR1A, HTR1E CYP1A2 161/4885CYP3A4 329/4885CYP2D6 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.